Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc., listed under ticker UPTD, is a clinical-stage biopharmaceutical company that accessed public markets through a special purpose acquisition company structure, operating in the immunotherapy and oncology sector. The company filed an 8-K with the Securities and Exchange Commission on September 18, 2023, notifying investors of a material corporate event. Estrella's route to public markets via blank-check vehicle reflects a pattern seen broadly among early-stage life-sciences firms pursuing SPAC mergers as an alternative to traditional initial public offerings. For comprehensive filing history, transaction timelines, and real-time status tracking on UPTD and the wider SPAC universe, sign up for full data access at SpacDesk.